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Abstract
Background: To identify markers for earlier diagnosis of severe pneumonia, we assess the correlation between
serum cytokine profile of children with different pneumonia severity.
Methods: In 25 hospitalized children, 7 with mild pneumonia and 18 with severe pneumonia, the serum concentration
of 11 cytokines in three sampling times were dosed. Statistical analysis included parametric and non-parametric tests,
Pearson correlation and ROC curve for cut-off definition of cytokines.
Results: At admission, IL-6 serum levels were high in mild or severe pneumonia, and was associated to vomiting (P = 0.
019) in both groups; and also to dyspnea (P = 0.012) and white blood cell count (P = 0.045) in patients with severe
pneumonia. IL-10 levels were also high in patients with pneumonia and were associated to lymphocytosis (P = 0.025).
The ROC curve of the IL-6:IL-10 serum levels ratio discriminated severe pneumonia cases at admission, and persistence
of infection in the third day of antibiotic therapy, with positive predictive values of 93% and 89%, respectively.
Conclusions: The balance between IL-6 and IL-10 serum levels showed to be a more discriminative marker for severity
definition and evaluation of recovery in patients with pneumonia.
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Background
Community acquired pneumonia (CAP) is a serious ill-
ness of the lower respiratory tract, responsible for high
morbidity in children, especially those younger than five
years old [1–3]. The World Health Organization (WHO)
uses clinical manifestations as a parameter for definition
of severity ratings (pneumonia and severe pneumonia)
[4]. The gradient of clinical severity arises from a com-
plex interaction between environmental factors, patho-
genicity of the etiologic agent and host characteristics,
including immunological competence, malnutrition,
anemia and other comorbidities [5–13]. Clinical data
associated to blood count and serum level of the C-
reactive protein (CRP) are determinants for therapeutic
management of acute respiratory disease in clinical prac-
tice [3, 14–16]. Blood count and serum levels of CRP are
low-cost laboratory tests, accessible in health services in
countries with limited resources and their results help
the differentiation between viral or bacterial respiratory
infection [3, 14, 17]. High levels of CRP are caused bythe
activity of circulating tumor necrosis factor (TNF) in the
liver as a response to the infectious process; therefore,
CRP is considered a nonspecific marker [18].
Recently, serum and bronchoalveolar levels of cyto-
kines have been related to severity of pulmonary inflam-
matory process [9, 19–21]. During the early stages of
pneumonia, the alveolar macrophages produce a variety
of cytokines and inflammatory chemokines, which at-
tract and activate polymorphonuclear leukocytes that
will mount an appropriate immune response in the lung
parenchyma [22–24]. Circulating levels of TNF, Interleu-
kin (IL)-1, IL-6, IL-8, IL-12 and interferon-gamma (IFN-
γ) are found in patients with CAP [7, 9, 19–21]. The
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cytokines IL-1, TNF and IL-6 are important for the acute
phase response [7, 9, 25], while modulation of inflamma-
tory responses of the airways is related to the expression of
the anti-inflammatory cytokines,IL-10 and IL-4 [6, 8, 24].
Studies on the inflammatory process during acute respira-
tory disease have reported conflicting results. Most studies
that seek to relate the severity of acute respiratory dis-
ease with cytokines serum levels have evaluated cyto-
kine levels in a single time point and samples were
collected from adult patients, who may have different
inflammatory responses from those observed in chil-
dren due to the anatomical-functional differences of the
pulmonary alveoli, in addition to the immune system im-
maturity [7, 9–13, 21, 26]. The aim of the present study
was to evaluate the correlation between the cytokines pro-
file in the serum of children and adolescents with different
pneumonia severity, defined by clinical manifestations and
alterations in the blood count, in order to identify markers
for early diagnosis of severe pneumonia.
Methods
Design and the subjects of the study
This was an observational, prospective and exploratory
study, which investigated the association between serum
cytokines levels with pneumonia severity. The classifica-
tion of clinical severity was based on the criteria defined
by WHO and established in the Brazilian Guidelines for
CAP in Pediatrics [3]. Briefly, cough or tachypnea (re-
spiratory rate ≥ 50 breaths per minute in an infant or ≥
40 breaths per minute in one year or older children)
with radiological evidence of pulmonary consolidation
was defined as pneumonia. We considered severe pneu-
monia either the presence of chest indrawing in chil-
dren with cough or difficult breathing, which were
criteria for severe pneumonia by WHO, or presence of
severe respiratory distress or inability to drink or cen-
tral cyanosis in a child with cough or difficult breath-
ing, which are criteria for classification of a very severe
pneumonia by WHO. Cytokine levels of children with
pneumonia were compared with cytokine levels of
children with severe pneumonia.
The patients evaluated in the present study were
admitted to three hospitals (Hospital da Restauração,
Hospital Helena Moura and the Instituto de Medicina
Integral Professor Fernando Figueira—IMIP) in the
municipality of Recife, northeastern Brazil, from June to
December 2012. All three hospitals belong to the net-
work of public health assistance of the Brazilian Health
System (Sistema Único de Saúde—SUS).
The exclusion criteria were age under six months, pre-
vious history of immunodeficiency, clinical suspicion of
tuberculosis, heart disease, neurological disease, cystic
fibrosis, bronchiolitis obliterans and severe persistent
asthma. Children that were transferred from other
hospitals, and were using antibiotics therapy for more than
3 days at the admission were also excluded, because we
were not able to collect biological samples for analysis in
two of three time points defined in the research protocol.
The present study was approved by the Research Ethics
Committees of the IMIP hospital (protocol 2886) and the
Hospital da Restauração (protocol CAAE-0014.0.102.000-
11). A clearance letter was also issued by the Health Secre-
tary of the state of Pernambuco authorizing the research
implementation in the Hospital Helena Moura. Data col-
lection was performed after obtaining written Informed
Consent signed by the children’s legal guardian.
Definition of variables
A form containing demographic (age, gender, place of
residence, socio-economic conditions) and clinical ques-
tions (duration of the disease, general symptoms and
related acute respiratory disease, including fever, cough-
ing, difficult breathing, subcostal recession, cyanosis and
nasal flaring, respiratory frequency, heart rate and oxy-
gen saturation) was filled out at hospital admission for
each patient. Presence of complications, such as pleural
effusion, respiratory insufficiency and anemia were also
investigated. Hemoglobin levels lower than 11,11.5 or
12 g/dL defined anemia for children less than five years
old, children 5 to 11 years old and adolescents 12 to
14 years old, respectively [27]. Oxygen saturation and heart
rate were evaluated in patients with no oxygen supply
using the Rossmax Pulse Oximeter SB100. Respiratory fre-
quency was defined as the number of breaths per minute.
Chest x-ray and blood tests were performed at hospital
admission. Blood samples were collected for cytokine dos-
age in three sampling times: on the day of admission (D0)
before any medical intervention; three days after the thera-
peutic scheme had started (D3), when a clinical improve-
ment of 80% in children treated with proper antibiotics is
expected; and eight days (D8) after the therapeutic scheme
had started, when complete illness resolution is expected.
Cytokines analysis
Peripheral blood samples were collected and sent to the
laboratory within 40 min. The cytokines IL-8, IL-1β, IL-
6, IL-10, TNF, IL-12p70 and IL-17A, IL-2, IL-4, IFN-γ
were evaluated by the BD™ Cytometric Bead Array Hu-
man Inflammation reagents and the Human Th1/Th2/
Th17 Cytokine kit. These tests were chosen because they
allow the quantification of several cytokines simultan-
eously using a small sample volume. The analysis of IL-5
expression was performed by immunoassay using the
BD OptEIA® Human IL-5 reagent, as recommended by
the manufacturer (Becton Dickinson, Franklin Lakes,
New Jersey). Of 25 children, cytokines serum levels
were determined in 23 at admission, and 17 on D3 and
D8 of treatment.
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Data analysis and statistics
Numerical variables, including age, respiratory and heart
frequency and oxygen saturation among others, were
subjected to the normality test of Kolmogorov-Smirnov,
and those that did not present normal distribution were
expressed by median, minimum and maximum values.
The median difference was assessed by Mann–Whitney
U non-parametric test. Categorical data were analyzed
using absolute and relative frequency tables and com-
parative analysis of the two studied groups (pneumonia
and severe pneumonia) was performed by the Chi-
square test or the Fisher’s 2-tailed test,when indicated.
The non-parametric Friedman test with its respective
post-hoc was used for intra-group analysis. A signifi-
cance level of 5% was considered in all analyzes.
The correlation between cytokine levels, clinical vari-
ables and blood count were evaluated by Pearson correl-
ation coefficient, except for the subcostal recession
variable, which was analyzed by the Spearman’s coeffi-
cient. The ROC curve, area under the curve, sensitivity,
specificity, positive and negative predictive value were
used to find the cut-offs for the IL6 and IL6:IL10 ratio
levels. The statistical analyzes and graphics were per-
formed using the Action 26 Excel software (Microsoft,




Of the 25 children evaluated in the present study, 7 were
diagnosed with pneumonia and 18 with severe pneumo-
nia. Almost all patients had an updated and complete
vaccination scheme (92%), were breast fed (88%) and
had adequate weight for age (96%). Three patients (12%)
lived with more than seven people in the same house-
hold, most patients (80%) were from the countryside of
the state of Pernambuco, and a third (32%) of the re-
spondents reported the presence of smokers at home.
Low maternal schooling was common among the
children’s legal guardians (96%).
Severe pneumonia was more frequent among children
younger than 5 years old (P = 0.027), and there was no
difference in disease severity between gender (P = 0.656).
Coughing and fever were observed in all patients of both
groups. However, the duration of fever (P = 0.000) and
anorexia (P = 0.023) during hospitalization were longer
in severe patients. The most frequent symptoms in
patients with severe pneumonia were subcostal reces-
sion (P < 0.000), difficult breathing (P = 0.007), O2 sat-
uration (P = 0.011), wheezing (P = 0.032) and vomiting
(P = 0.021) (Additional file 1: Table S1).
Anemia occurred in 61.1% of the patients with severe
pneumonia and leukocytosis was observed in both stud-
ied groups. The median leukocyte count was higher in
the pneumonia group than in children with severe pneu-
monia, but with no statistical difference between the two
groups. Patients with severe pneumonia were diagnosed
later (median of 10 days) than children with pneumonia
(median of 7 days) (P = 0.023).
Of the 18 patients with severe pneumonia, 11 (61%)
needed chest drainage for a median of 11 days (range 4
to 29 days). Biochemical analysis and pleural fluid culture
were not performed in any of the cases. In nine patients
with severe pneumonia (50%), oxygen was supplied by a
Venturi mask for a median of 7 days.
Cytokine profile of patients with pneumonia and severe
pneumonia
Serum circulating levels of TNF, IL-1β, IL-8, IL-17 and
IL-5 in the three sampling times were similar for both
studied groups. At diagnosis, IL-10 levels were lower
(3.68 vesus 1.99, P = 0.074), and IL-6 levels were higher
(44.07 versus 19.98, P = 0.155) in children with severe
pneumonia than in children with non-severe pneumo-
nia; however, no statistical difference was observed
between the two groups. Furthermore, IL-6 serum
levels significantly reduced in patients with pneumonia
(P = 0.041) and severe pneumonia (P = 0.001) during
recovery (Table 1).
There was a correlation between some cytokines and
the clinical signs of severity and nonspecific symptoms re-
lated to the infection. In patients with severe pneumonia
and pneumonia, IL-6 levels were associated with vomiting;
however, in the severe pneumonia group, IL-6 levels were
also associated to dyspnea, suggesting that this cytokine
plays a role in pneumonia severity (Table 2).
In patients with pneumonia at hospital admission, IL-10
was associated to lymphocytosis (P = 0.025), and in pa-
tients with severe pneumonia, the proliferation of defense
cells was demonstrated by the positive association be-
tween IL-6 levels and leukocyte count (P = 0.045) and the
levels of TNF (P = 0.025) and IL-1β (P = 0.040) with
monocytosis (Table 2).
Pneumonia recovery and cytokines profile
Oxygen saturation, temperature, respiratory and cardiac
frequencies are predictive paramenters for pneumonia se-
verity, and were evaluated at admission, on D3 and D8 of
hospitalization for all children (Additional file 2: Table S2).
At admission, O2 saturation was the most important cri-
terion of severity (94% for severe pneumonia versus 98%
for non-severe pneumonia, P = 0.011), but no significant
differences were found in temperature and respiratory or
cardiac frequencies. On day D3 of hospitalization, besides
the O2 saturation difference (P = 0.021), it was possible to
distinguish severe pneumonia from non-severe cases
based on respiratory frequency (P = 0.030) and persistence
of fever (P = 0.000). On D8 of hospitalization, O2
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saturation and persistence of fever were not predictive pa-
rameters for pneumonia severity, but high respiratory fre-
quency still predicted disease severity (P = 0.008).
Considering data of children who had all three sam-
ples (D0, D3 and D8) collected, we performed a longi-
tudial analysis for temporal evaluation of the clinical
signs recovery. Children with non-severe pneumonia
had significant temperature improvement on D3 (P =
0.002). On the other hand, in patients with severe
pneumonia, no statistical difference was observed from
D0 to D3 (P = 0.393), but a significant temperature
change occurred from D3 to D8 (P = 0.001). The im-
provement of the respiratory frequency was also faster
in patients with non-severe pneumonia than in patients
with severe pneumonia. In non-severe pneumonia
group, a significant difference of the respiratory fre-
quency occurred from D0 to D3 (P = 0.012), while in
patients with severe pneumonia, the difference was only
noticeable on D8 in comparison with D3 (P = 0.014) or
D0 (P = 0.001) (Additional file 2: Table 2).
Regarding the cytokine levels, the reduction of IL-6
serum levels during recovery of children with severe
pneumonia was the effect more pronuanced (Fig. 1). The
ratio between the median of IL-6 and IL-10 serum levels
in patients with severe and non-severe pneumonia was
respectively 22 and 5 at admission, but 9 and 5 on D3,
and 3 and 2 on D8 of antibiotics therapy.
According to the ROC curve analysis, at hospital ad-
mission, IL-6 serum levels equal or higher than 21.1 pg/
mL and IL-6:IL-10 ratio of at least 9.61 may discriminate
severe pneumonia from mild disease with a sensitivity of
76.5%, corresponding to a positive predictive value of
93% (Table 3). Furthermore, in the third day of antibi-
otics therapy, IL6:IL10 serum levels higher than 5.0 pre-
dict persistence of the symptoms and may help medical
decision in adjusting the therapeutics for severe cases,
and discharge mild pneumonia cases. The decrease in
the IL-6:IL-10 ratio to 3 in patients with severe pneumo-
nia on D8 coincided with the temperature and respira-
tory frequency recovery to normal levels.
Discussion
Pneumonia is a disease associated to poverty conditions
related to the environment, the individual, the infectious
agent and the healthcare services [3, 4, 28–30]. In the
present study, we adopted the criteria published in the
Brazilian guidelines for community acquired pneumonia
in pediatrics, which follows the former guidelines of
WHO [3], allowing that patients (5–10% of the cases)
with hidden pneumonia, which is characterized by fever
and coughing, with or without radiographic changes,
and improvement after empirical treatment, may be di-
agnosed at an early stage [1, 31, 32]. Thus, patients with
fever, coughing, tachypnea and radiological changes were
diagnosed with pneumonia, and those with subcostal re-
cession were classified with severe pneumonia. In our
casuistic, factors such age, anorexia, sibilance, difficult
breathing, and vomiting were statistically correlated with
pneumonia severity what corroborates with other studies
[30, 33–36]. Presence of abdominal pain in children with
pneumonia was observed by us as reported by other
authors, but without any association with the disease
severity [34, 37]. Anemia has a high prevalence in our
midst, as demonstrated by Carvalho et al., who found a
prevalence of 92% of healthy children in day care centers
in the public health network with hemoglobin levels <
11.0 g/dL; but it was not also associated to severe pneu-
monia [12, 38]. The elapsed time between the beginning
of the disease and its diagnostic, which can be related to
the difficult access to the health services, was associated
with disease severity, corroborating with other studies
carried out in Brazil and Africa [33, 39]. Coincidently, all
children under 5 years old were from countryside and
presented severe pnuemonia. In this case, two aspects
Table 1 Cytokine profiles of patients with pneumonia according to severity and disease duration
Severe pneumonia Non-severe pneumonia Severe x non-severe pneumonia
Cytokines (days) Q1 Q3 Median *P-value Q1 Q3 Median **P-value ***P-value
IL10 (D0) 1.50 2.68 1.99 2.44 4.05 3.68 0.074
IL10 (D3) 1.35 3.59 1.92 1.41 6.12 2.31 0.441
IL10 (D8) 1.99 5.55 2.59 0.417 1.72 11.43 2.16 0.549 1.000
IL6 (D0) 26.62 108.47 44.07 13.55 445.55 19.98 0.155
IL6 (D3) 9.27 40.48 16.45 4.95 56.34 11.13 0.959
IL6 (D8) 3.27 15.32 8.41 0.001 2.98 12.66 4.94 0.041 0.442
Note
*P-value is related to the difference in serum cytokines levels in D0, D3 and D8 for children with severe pneumonia
**P-value is related to the difference in serum cytokines levels in DO, D3 and D8 for children with non-severe pneumonia (intragroup analysis considered children
with all three samples evaluated)
***P-value is related to comparisons of serum cytokine levels between group of children with severe and non-severe pneumonia in each time point D0, D3 or D8
(Intergroup analtsis considered all samples collected for each time point). Q1, first quartil, and Q3, thrird quartil. P-value ≤ 0.05 was considered significant,
significant values are shown in bold
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Table 2 Correlation between clinical signs and blood count with cytokines serum levels of patients with severe and non-severe pneumonia
IL-12p70 TNF IL-10 IL-6 IL1β IL-8 IFN IL-17A IL5 IL-6/IL-10
r P r P r P r P r P r P r P r P r P r P
Severe pneumonia
Clinical signs (days)
Abdominal pain 0.30 0.263 0.06 0.812 0.03 0.923 0.05 0.844 0.38 0.147 0.32 0.229 0.07 0.803 0.78 0.799 −0.37 0.150 0.04 0.897
Sickness −0.03 0.906 −0.11 0.676 −0.09 0.742 0.03 0.902 −0.08 0.759 −0.12 0.661 −0.47 0.093 −0.42 0.153 −0.26 0.306 0.05 0.842
Fever 0.33 0.208 0.25 0.359 0.28 0.293 0.46 0.073 0.35 0.190 −0.13 0.644 −0.29 0.315 −0.38 0.196 −0.36 0.155 0.43 0.097
Anorexia −0.07 0.795 −0.04 0.874 −0.24 0.374 0.30 0.263 −0.43 0.097 −0.09 0.731 −0.26 0.377 −0.19 0.530 0.08 0.766 0.31 0.238
Dyspnea −0.03 0.905 −0.02 0.945 −0.12 0.654 0.61 0.012 0.34 0.196 0.27 0.308 −0.09 0.761 −0.2 0.523 −0.39 0.126 0.62 0.010
Subcostal recession 0.15 0.568 0.14 0.600 −0.14 0.605 0.03 0.918 0.36 0.166 −0.08 0.757 0.53 0.053 −0.15 0.615 −0.05 0.842 0.20 0.467
Difficult breathing −0.10 0.715 0.09 0.736 −0.21 0.443 −0.05 0.862 0.09 0.738 0.23 0.388 −0.12 0.692 −0.17 0.581 0.18 0.484 −0.01 0.980
Chest pain −0.18 0.518 0.01 0.971 −0.21 0.443 0.08 0.785 −0.12 0.676 −0.28 0.311 −0.23 0.454 −0.33 0.264 −0.03 0.912 −0.17 0.540
Coughing −0.12 0.667 −0.02 0.532 −0.43 0.095 0.06 0.827 −0.44 0.090 −0.34 0.199 −0.39 0.165 −0.43 0.145 −0.35 0.167 0.11 0.688
Vomiting −0.31 0.211 −0.24 0.376 0.16 0.549 0.58 0.019 −0.12 0.669 −0.08 0.761 0.22 0.447 0.28 0.362 −0.02 0.939 0.55 0.028
Blood count
Hemoglobin −0.06 0.814 −0.18 0.517 −0.16 0.556 0.18 0.516 −0.12 0.662 −0.62 0.011 −0.03 0.919 −0.25 0.417 −0.35 0.167 0.18 0.513
Leukocytes −0.34 0.204 −0.25 0.357 −0.11 0.674 0.51 0.045 −0.08 0.779 −0.24 0.371 0.4 0.152 0.31 0.309 −0.28 0.277 0.52 0.037
Hemacias −0.29 0.275 −0.41 0.114 −0.15 0.57 0.08 0.757 −0.27 0.306 −0.23 0.402 −0.07 0.809 −0.05 0.866 −0.44 0.081 0.08 0.762
Neutrophils −0.09 0.753 −0.15 0.583 −0.25 0.351 0.43 0.1 −0.32 0.228 −0.37 0.164 −0.27 0.357 −0.29 0.346 −0.21 0.419 0.44 0.088
Eosinophils −0.07 0.805 −0.09 0.755 −0.1 0.735 −0.13 0.639 0.23 0.413 −0.48 0.069 −0.18 0.552 −0.16 0.616 0.35 0.18 −0.10 0.720
Lymphocytes 0.26 0.323 0.37 0.157 0.32 0.229 −0.33 0.218 0.45 0.084 0.46 0.071 0.32 0.268 0.31 0.307 0.4 0.114 −0.33 0.212
Monocytes 0.34 0.204 0.56 0.025 0.32 0.223 −0.29 0.282 0.52 0.04 0.26 0.332 0.16 0.587 0.07 0.819 0.02 0.954 −0.29 0.279
Platelets 0.01 0.963 0.11 0.673 −0.09 0.746 −0.21 0.431 −0.07 0.807 0.37 0.157 −0.02 0.955 0.06 0.84 0.42 0.09 −0.20 0.466
Non-severe Pneumonia
Clinical signs (days)
Abdominal pain 0.91 0.012 0.89 0.019 0.81 0.049 0.35 0.503 0.81 0.054 0.40 0.430 −0.38 0.534 −0.56 0.443 −0.38 0.406 0.34 0.514
Sickness 0.29 0.579 0.29 0.287 0.41 0.418 −0.62 0.19 −0.30 0.569 −0.54 0.273 −0.31 0.612 −0.92 0.077 0.38 0.401 −0.62 0.185
Fever 0.53 0.283 0.17 0.748 0.71 0.112 0.06 0.912 0.22 0.680 −0.06 0.909 0.11 0.856 0.10 0.897 −0.21 0.659 −0.17 0.745
Anorexia −0.08 0.887 0.32 0.538 −0.02 0.975 0.36 0.479 0.57 0.237 0.30 0.561 −0.17 0.781 −0.28 0.722 −0.25 0.591 0.11 0.832
Dyspnea −0.12 0.822 −0.23 0.658 0.19 0.722 −0.10 0.852 −0.18 0.739 −0.23 0.666 −0.24 0.693 −0.32 0.681 0.29 0.535 −0.11 0.837
Subcostal recession - - - - - - - - - - - - - - - - - - - -
Difficult breathing −0.13 0.809 0.32 0.543 −0.12 0.824 −0.19 0.371 0.18 0.739 −0.17 0.744 −0.38 0.534 −0.38 0.616 0.33 0.465 −0.20 0.707
Chest pain - - - - - - - - - - - - −0.25 0.685 - - 0.28 0.550 - -















Table 2 Correlation between clinical signs and blood count with cytokines serum levels of patients with severe and non-severe pneumonia (Continued)
Vomiting −0.09 0.884 0.13 0.839 −0.21 0.731 1.00 <0.001 0.73 0.164 0.99 0.001 - - - - −0.58 0.229 1.00 <0.001
Blood count
Hemoglobin 0.62 0.189 0.24 0.641 0.54 0.27 0.3 0.57 0.42 0.402 0.23 0.66 0.97 0.006 0.97 0.031 −0.82 0.024 0.29 0.575
Leukocytes −0.55 0.256 −0.35 0.496 −0.68 0.138 0.49 0.328 0.16 0.765 0.44 0.387 0.54 0.348 0.72 0.282 −0.48 0.273 0.49 0.319
Hemacias −0.45 0.371 −0.56 0.251 −0.65 0.166 0.29 0.571 −0.23 0.666 0.31 0.552 0.71 0.178 0.74 0.256 −0.49 0.268 0.31 0.551
Neutrophils −0.64 0.172 −0.21 0.688 −0.76 0.078 0.49 0.321 0.2 0.699 0.5 0.311 −0.01 0.987 0.1 0.9 −0.18 0.707 0.50 0.313
Eosinophils 0.49 0.325 0.19 0.714 0.71 0.113 −0.38 0.455 −0.13 0.813 −0.43 0.399 −0.31 0.61 −0.4 0.597 0.33 0.467 −0.39 0.440
Lymphocytes 0.73 0.097 0.47 0.346 0.87 0.025 −0.48 0.333 −0.01 0.986 −0.47 0.345 −0.45 0.443 −0.62 0.379 0.3 0.516 −0.49 0.320
Monocytes 0.08 0.888 −0.24 0.646 0.36 0.483 −0.44 0.386 −0.39 0.448 −0.56 0.247 0.02 0.98 −0.09 0.913 0.23 0.623 −0.45 0.374
Platelets −0.42 0.411 −0.4 0.438 −0.34 0.506 −0.48 0.338 −0.71 0.115 −0.4 0.43 −0.39 0.519 −0.56 0.439 0.7 0.08 −0.47 0.346















should be considered. First, a possible delay in diagnosis
and treatment in the residence’s town may have contrib-
ute to an hemodynamic instability and ICU requirement
at admission in the hospital; secondly, the innate im-
munity of young children may be compromised by less
bactericidal activity and inflammatory response by im-
mature neutrophils, and poor cytokine response by mac-
rophages and monocytes [40].
Inflammation biomarkers, as cytokines, may be useful
in determining the magnitude of the inflammatory
response and lung injury in children with pneumonia.
However, studies that tried to associate clinical severity
in adult [18, 21, 41] and children [42] patients with re-
spiratory diseases and serum levels of cytokines had con-
troversial results. In the present study, the cytokines,
TNF, IL-1β, IL-6, IL-8, IL-12p70, IFN-γ, IL-17A, IL-10
and IL-5, were detected in the serum of children with
pneumonia and severe pneumonia at hospital admis-
sion, and IL-6 was the only cytokine associated with
disease severity.
Fig. 1 Balance between IL-6 and IL-10 during recovery from pneumonia of different severity. Seric levels of IL-6 (left) and IL-10 (middle) cytokines,
and the ratio of seric levels of IL-6:IL-10 (right) in group of children diagnosed with non-severe pneumonia (top) or severe pneumonia (bottom).
IL-6 levels, in non-severe pneumonia, at admission x D8 (P = 0.025); IL-6 levels, in severe pneumonia, at admission x D3 (P = 0.003) and at
admission x D8 (P = 0.003); Ratio IL-6:IL-10, in non-severe pneumonia, at admission and D3 (P = 0.025) and D3 x D8 (P = 0.025); Ratio IL-6:IL-10, in severe
pneumonia, at admission x D3 (P = 0.005); at admission and D8 (P = 0.005) and D3 x D8 (P = 0.034)






CI 95% Time-points Severe pneumonia Non-severe
pneumonia
CI 95%
At admission Sen = 76.5 49.8 – 92.2 At admission Sen = 76.5 49.8 – 92.2
>21.1 13 1 Spec = 83.3 36.5 – 99.1 >9.61 13 1 Spec = 83.3 36.5 – 99.1
≤21.1 4 5 PPV = 92.9 64.2 – 99.6 ≤9.61 4 5 PPV = 92.9 64.2 – 99.6
NPV = 55.6 22.7 – 84.7 NPV = 55.6 22.7 – 84.7
D3 Sen = 58.3 28.6 – 83.5 D3 Sen = 72.7 39.3 – 92.7
>11.28 7 2 Spec = 60.0 17.0 – 92.7 >5.00 8 1 Spec = 80.0 29.9 – 98.9
≤11.28 5 3 PPV = 77.8 40.2 – 96.1 ≤5.00 3 4 PPV = 88.9 50.7 – 99.4
NPV = 37.5 10.2 – 74.1 NPV = 57.1 20.2 – 88.2
D8 D8
>5.07 8 2 Sen = 66.7 35.4 – 88.7 >2.40 7 1 Sen = 63.6 31.6 – 87.6
≤5.07 4 3 Spec = 60.0 17.0 – 92.7 ≤2.40 4 4 Spec = 80.0 29.9 – 98.9
PPV = 80.0 44.2 – 96.5 PPV = 87.5 46.7 – 99.3
NPV = 42.9 11.8 – 79.8 NPV = 50.0 17.4 – 82.6
Note: D0 day of admission, D3 third day and D8 - eighth day of hospitalization, Sen sensitivity, Spec specificity, PPV positive predictive value, NPV negative
predictive value, CI confidence interval
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At admission (D0), we observed high serum levels of cy-
tokines, predominantly pro-inflammatory including TNF,
IL-1β, IL-6 and IL-8, which are involved in the innate im-
mune response and in the immune response development
[22, 43, 44]. In patients with severe pneumonia, the IL-6
levels were positively associated with high levels of leuko-
cytes while the levels of TNF and IL-1β were associated
with monocytes, possibly related to the recruitment and
differentiation of macrophages at the site of inflammation.
According to Bauer et al., TNF and IL-1β are associated
with lung injury in acute respiratory distress syndrome
and in severe pneumonia, although in a smaller magni-
tude [21]. A study reported by Kolsuz et al. on inflamma-
tory cytokines (TNF, IL-1β, IL-6 and IL-8) levels in
bronchoalveolar material after 24 h of admission for adult
patients with pneumonia showed IL-6 as the most import-
ant cytokine in the determination of the disease severity in
patients with systemic inflammatory response syndrome
[45]. In other study, Antunes et al. reported high levels of
IL-6, TNF-α, IL-10 and IL-1β detected in the majority of
the 24 patients with CAP at admission, but the cytokines
levels decreased significantly on days three and five of
hospitalization, and IL-6 was the only cytokine associated
with the disease severity, as ours findings [9].
High levels of IL-6 were observed in both studied groups
at admission, highlighting the importance of this cytokine
in the pulmonary inflammatory process regardless the dis-
ease severity [9]. Although IL-6 levels have been correlated
with vomiting, which is a clinical manifestation of disease
severity, other causes, such as the use of medications and
inflammatory systemic process, may implicate in the eti-
ology of vomiting and abdominal pain [34, 37]. IL-6 was
also positively correlated with dyspnea, which may repre-
sent, under the point of view of the pathophysiology, the in-
tensity of the lung’s inflammatory process, which is
associated with respiratory disease severity.
An important anti-inflammatory cytokine in pneumonia
is IL-10. In the present study, IL-10 levels were higher in
the group of patients with pneumonia than in patients
with severe pneumonia in admission (1.99 x 3.68 pg/mL;
P = 0.074). Although the statistical differences were not
significant what may be related to the small number of
samples, the increased levels of IL-10 in patients with
pneumonia was associated with high levels of lymphocytes,
suggesting that IL-10 is an important modulatory factor of
the inflammatory response of acute pneumonia [6, 24].
Conclusion
In conclusion, the controversial results of some studies re-
garding the correlation of IL-6 serum levels and pneumonia
severity may be produced by the choice of disease time
point analysed and the balance between IL-6 and IL-10
serum levels. Our findings showed the ratio between the
serum levels of IL-6 and IL-10 is an important criteria for
severity definition at hospital admission, allowing to screen-
ing at the emergency room who is at risk of evolving into
complication, and evaluation of recovery capacity. Specially
in the third day of antibiotic therapy, when the patients’
clinical condition is usually evaluated for possible changing
in the treatment protocol, an IL-6:IL-10 ratio higher than
5.0 may predict that 89% of positive cases have still severe
pneumonia, indicating that changes in the treatment proto-
col might be needed. In future, the determination of IL-6
and IL-10 serum levels may be offered by routine labora-
tory as one more marker to evaluate the severity of infec-
tion disease at the diagnosis.
Additional files
Additional file 1: Table S1. Clinical features of children with severe
pneumonia and non-severe pneumonia. The differences between the
clinic of children with severe and non-severe pneumonia included anorexia,
wheezing, respiratory difficulty, subcostal recession, O2 saturation, but not
respiratory or heart frequencies, fever or caughing; the duration of fever and
hospitalization was longer in severe pneumonia. (DOC 75 kb)
Additional file 2: Table S2. Temporal evolution of clinical signs of patients
according the pneumonia severity. Comparison of clinical signs inside
the severe pneumonia group (Intragroup analysis) between different
sampling times showed that changes in corporal temperature, O2 saturation
and respiratory frequency were observed only in the eighth day (D8)
of hospitalization; while in non-severe pneumonia group changes on
corporal temperature and respiratory frequency were observed in the
third day (D3) of hospitalization, confirming the delay recovery of severe
pneumonia. Intergroup analysis corresponded to the comparison of
clinical signs between severe and non-severe pneumonia groups in
each time-point and showed significative differences in O2 saturation
on D3 and D8 in relation to diagnosis (D0), as expected since it definies
disease severity; differences in corporal temperature on D3 and respiratory
frequency on D3 and D8 showed to be helpful to distinguish cases
with unfavored evolution, since non-severe pneumonia recovery faster.
(DOC 62 kb)
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